{"id":"W1983180167","doi":"10.1007/s10637-009-9367-9","title":"Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"Pharmaceuticals Bayer","keywords":"Sorafenib; Medicine; Discontinuation; Rash; Adverse effect; Placebo; Randomized controlled trial; Internal medicine; Soft tissue sarcoma; Nausea; Surgery; Sarcoma; Tolerability; Oncology; Soft tissue; Pathology; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003073635,0.001437279,0.002837091,0.0003132749,0.0005908095,0.001118575,0.0005450348,0.0007716943,0.002643441],"category_scores_gemma":[0.002963142,0.0004009606,0.002440615,0.0004617282,0.0008697672,0.001075305,0.0003918185,0.002163754,0.0003931333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005893318,"about_ca_system_score_gemma":0.0008936683,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003254272,"about_ca_topic_score_gemma":0.0008616376,"domain_scores_codex":[0.9989221,0.0006182981,0.00007715022,0.0001687779,0.00006266098,0.0001510743],"domain_scores_gemma":[0.9979774,0.0007390006,0.0004982159,0.0002496151,0.0001328511,0.0004028555],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8904697,0.004307212,0.04611303,0.0004762575,0.003395773,0.0005190148,0.0002902037,0.001278836,0.01072332,0.0002746923,0.002498345,0.03965366],"study_design_scores_gemma":[0.7366465,0.135121,0.1076459,0.00008857054,0.006369886,0.001584519,0.0003125566,0.002922552,0.003043694,0.00117957,0.004990844,0.00009460043],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974924,0.0009401405,0.0002095412,0.0002973095,0.00004499627,0.0002178275,0.000422251,0.00001206988,0.000363493],"genre_scores_gemma":[0.9969708,0.0004848846,0.0002838889,0.0002636043,0.0001033145,0.0002744297,0.00129078,0.000008523504,0.0003198372],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003073635,"threshold_uncertainty_score":0.01625514,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01175126435780694,"score_gpt":0.278792244268608,"score_spread":0.2670409799108011,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}